Home » Binocular eye tracking-based device is non-inferior to patching for the treatment of amblyopia

Binocular eye tracking-based device is non-inferior to patching for the treatment of amblyopia

by admin

1. In a small randomized controlled trial, children with amblyopia using a newly developed binocular twinocular home device had similar visual acuity at 16 weeks as children with a patch to their dominant eye.

2. Treatment adherence was significantly higher in the device group than in the patched group, with 91% compared to 83%.

Evidence Rating Level: 1 (excellent)

Research overview: Amblyopia is a common disorder in which vision in one eye is reduced due to abnormalities during visual development, such as uneven refractive errors and strabismus. It is traditionally treated with monocular therapy and punished with patches or mydriatics in the dominant eye, but in recent years several new binocular treatments have been developed. A blurred dichroic (separate for each eye) image is displayed in the dominant eye. This study aimed to evaluate the efficacy of one such device, CureSight, compared to patching. A total of 103 amblyopic patients were randomized to treatment with CureSight or patching for 16 weeks. At 16 weeks, amblyopic visual acuity improved significantly in both groups, meeting the primary endpoint of non-inferiority by 0.28±0.13 logMAR units in the CureSight group and 0.23±0.14 in the patched group. Visual acuity improved by 2 lines or more in the majority of patients in both groups. Stereopsis, which represents the use of both eyes, was also significantly improved in both groups, but did not differ between groups. Adherence to treatment based on total treatment time was 91% in the CureSight group and 83% in the patching group. This small randomized trial convincingly demonstrates non-inferiority to patching, making the CureSight device one of the most rigorously studied and therefore useful binocular treatment systems recently developed. A new treatment option. Adherence was much higher with the device, but it is much more expensive and complex to implement than patching without showing excellent or stereoscopic results in 16 weeks.

Click to read ophthalmic research

Related reading: Recent Advances in Amblyopia Screening and Treatment

detail [randomized controlled trial]: At multiple centers in Israel, children aged 4 to 9 years with amblyopic corrected visual acuity between 20/32 and 20/100 were randomized 1:1 to receive treatment between 2020 and 2022. I was. Patients with amblyopia due to major strabismus or changes in the past 16 weeks on prescription were excluded. Children in the CureSight group watched videos on a computer through glasses that selectively blurred the central vision of the dominant eye based on input from her eye tracker. CureSight treatment was 90 minutes, 5 days a week, and patching was her 2 hours, 7 days a week. About half of the patients had previously received patch therapy, and half had not. The primary non-inferiority outcome was based on a modified intention-to-treat analysis, but there were no significant differences in visual acuity differences in the per-protocol analysis as well. The difference in least-squares means between the CureSight and patch groups was 0.034 logMAR units of improvement in amblyopic visual acuity at 16 weeks, with a 90% confidence interval (CI) of -0.008 to 0.076, pre-defined. It was smaller than the non-visual one. -0.10 logMAR unit margin of inferiority. The between-group difference in stereoscopic change was 0, with a 95% CI of -0.27 to 0.27 (p=0.76). Differences in binocular visual acuity improvement at 16 weeks were also not significant.

Image: PD

©2022 2 Minute Medicine Co., Ltd.. all rights reserved. No work may be reproduced without the express written consent of 2 Minute Medicine Co., Ltd.. License inquiries hereNone of the articles should be construed as medical advice, nor should they be construed as such by the authors or 2 Minute Medicine, Inc.

You may also like

Leave a Comment